Jiangsu Hengrui Pharmaceuticals Co., Ltd.
SEC CIK 2080343 · EDGAR
Most active insiders at BRVE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | $64.80M | — |
| 2 | Chimovits Erez | Dir, 10% | $34.92M | — |
| 3 | ORBIMED ADVISORS LLC | Dir, 10% | $34.92M | — |
| 4 | AH Bio Fund IV, L.P. | 10% | $19.80M | — |
| 5 | Murdoch Travis | CEO, Pres, Dir | $1.50M | — |
| 6 | Viehbacher Christopher | Dir | $1.50M | — |
| 7 | Lubner David Charles | Dir | $1000.0K | — |
| 8 | Rickey James Paul | CFO | $500.0K | — |
| 9 | Malek David I | Dir | $75.0K | — |
| 10 | Anderson Michele A. | Chief Development Off | $20.0K | — |
| 11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% | — | — |
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-10 10:03 | 2026-08-07 | BRVE | Braveheart Bio, Inc. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% | C - Cnv Deriv | — | +7.42M | 7.42M | New | — |
| DM | 2026-04-22 06:03 | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% | C - Cnv Deriv | — | +11.51M | 2.03M | New | — |
Purchase Sale Sale after option exercise All abbreviations